{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T10:04:10Z","timestamp":1769767450190,"version":"3.49.0"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2017,5,5]],"date-time":"2017-05-05T00:00:00Z","timestamp":1493942400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Radius Pharmaceuticals"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,8,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:sec>\n                  <jats:title>\u2003<\/jats:title>\n                  <jats:p>Daily subcutaneous (SC) injections of the investigational drug abaloparatide-SC (80 mcg) for 18 months significantly decrease the risk of vertebral and nonvertebral fracture compared with placebo in postmenopausal women. We examined the efficacy of abaloparatide-SC as a function of baseline fracture risk, assessed using the FRAX tool. Baseline clinical risk factors (age, body mass index [BMI], prior fracture, glucocorticoid use, rheumatoid arthritis, and smoking) were entered into country-specific FRAX models to calculate the 10-year probability of major osteoporotic fractures, with or without femoral neck bone mineral density (BMD). The interaction between probability of a major osteoporotic fracture and treatment efficacy was examined by a Poisson regression. A total of 821 women randomized to placebo and 824 women to abaloparatide-SC, mean age 69 years in both groups, were followed for up to 2 years. At baseline, the 10-year probability of major osteoporotic fractures (with BMD) ranged from 2.3% to 57.5% (mean 13.2%). Treatment with abaloparatide-SC was associated with a 69% (95% confidence interval [CI] 38\u201385%) decrease in major osteoporotic fracture (MOF) and a 43% (95% CI 9\u201364%) decrease in any clinical fracture compared with placebo. For all outcomes, hazard ratios tended to decrease (ie, greater efficacy) with increasing fracture probability. Whereas the interaction approached significance for the outcome of any fracture (p\u2009=\u20090.11), there was no statistically significant interaction for any of the fracture outcomes. Similar results were noted when FRAX probability was computed without BMD. Efficacy of abaloparatide-SC to decrease the risk of major osteoporotic fracture or any clinical fracture in postmenopausal women with low BMD and\/or prior fracture appears independent of baseline fracture probability. \u00a9 2017 American Society for Bone and Mineral Research.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1002\/jbmr.3163","type":"journal-article","created":{"date-parts":[[2017,5,5]],"date-time":"2017-05-05T11:12:10Z","timestamp":1493982730000},"page":"1625-1631","source":"Crossref","is-referenced-by-count":48,"title":["The Effect of Abaloparatide-SC on Fracture Risk Is Independent of Baseline FRAX Fracture Probability: A Post Hoc Analysis of the ACTIVE Study"],"prefix":"10.1093","volume":"32","author":[{"given":"Eugene V","family":"McCloskey","sequence":"first","affiliation":[{"name":"Centre for Integrated research in Musculoskeletal Ageing (CIMA)Mellanby Centre for Bone ResearchUniversity of SheffieldSheffieldUK"},{"name":"Centre for Metabolic Bone DiseasesUniversity of SheffieldSheffieldUK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helena","family":"Johansson","sequence":"additional","affiliation":[{"name":"Institute for Health and AgingCatholic University of AustraliaMelbourneAustralia"},{"name":"Centre for Metabolic Bone DiseasesUniversity of SheffieldSheffieldUK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anders","family":"Oden","sequence":"additional","affiliation":[{"name":"Centre for Metabolic Bone DiseasesUniversity of SheffieldSheffieldUK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas C","family":"Harvey","sequence":"additional","affiliation":[{"name":"MRC Lifecourse Epidemiology UnitUniversity of SouthamptonSouthamptonUK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hai","family":"Jiang","sequence":"additional","affiliation":[{"name":"Radius Health, Inc.WalthamMAUSA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Modin","sequence":"additional","affiliation":[{"name":"Radius Health, Inc.WalthamMAUSA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorraine","family":"Fitzpatrick","sequence":"additional","affiliation":[{"name":"Radius Health, Inc.WalthamMAUSA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John A","family":"Kanis","sequence":"additional","affiliation":[{"name":"Institute for Health and AgingCatholic University of AustraliaMelbourneAustralia"},{"name":"Centre for Metabolic Bone DiseasesUniversity of SheffieldSheffieldUK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2017,5,5]]},"reference":[{"issue":"1","key":"2024021014201056700_jbmr3163-bib-0001","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1210\/en.2015-1726","article-title":"Binding selectivity of abaloparatide for PTH-type-1-receptor conformations and effects on downstream signaling","volume":"157","author":"Hattersley","year":"2016","journal-title":"Endocrinology"},{"issue":"2","key":"2024021014201056700_jbmr3163-bib-0002","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1210\/jc.2014-3718","article-title":"Effects of abaloparatide, a human parathyroid hormone-related peptide analog, on bone mineral density in postmenopausal women with osteoporosis","volume":"100","author":"Leder","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"2024021014201056700_jbmr3163-bib-0003","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1001\/jama.2016.11136","article-title":"Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial","volume":"316","author":"Miller","year":"2016","journal-title":"JAMA"},{"key":"2024021014201056700_jbmr3163-bib-0004","author":"Higgins"},{"issue":"8","key":"2024021014201056700_jbmr3163-bib-0005","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1007\/s00198-010-1474-0","article-title":"A meta-analysis of the effect of strontium ranelate on the risk of vertebral and nonvertebral fracture in postmenopausal osteoporosis and the interaction with FRAX((R))","volume":"22","author":"Kanis","year":"2011","journal-title":"Osteoporos Int"},{"issue":"4","key":"2024021014201056700_jbmr3163-bib-0006","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.bone.2010.06.009","article-title":"A meta-analysis of the efficacy of raloxifene on all clinical and vertebral fractures and its dependency on FRAX","volume":"47","author":"Kanis","year":"2010","journal-title":"Bone"},{"issue":"6","key":"2024021014201056700_jbmr3163-bib-0007","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/j.bone.2009.02.014","article-title":"Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX","volume":"44","author":"Kanis","year":"2009","journal-title":"Bone"},{"issue":"5","key":"2024021014201056700_jbmr3163-bib-0008","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1007\/s00198-008-0786-9","article-title":"Ten-year fracture probability identifies women who will benefit from clodronate therapy\u2014additional results from a double-blind, placebo-controlled randomised study","volume":"20","author":"McCloskey","year":"2009","journal-title":"Osteoporos Int"},{"issue":"11","key":"2024021014201056700_jbmr3163-bib-0009","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1007\/s00198-015-3173-3","article-title":"FRAX and the effect of teriparatide on vertebral and nonvertebral fracture","volume":"26","author":"Harvey","year":"2015","journal-title":"Osteoporos Int"},{"issue":"9","key":"2024021014201056700_jbmr3163-bib-0010","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1007\/s00198-015-3129-7","article-title":"Efficacy of weekly teriparatide does not vary by baseline fracture probability calculated using FRAX","volume":"26","author":"Harvey","year":"2015","journal-title":"Osteoporos Int"},{"issue":"9","key":"2024021014201056700_jbmr3163-bib-0011","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1002\/jbmr.5650080915","article-title":"Vertebral fracture assessment using a semiquantitative technique","volume":"8","author":"Genant","year":"1993","journal-title":"J Bone Miner Res"},{"issue":"1","key":"2024021014201056700_jbmr3163-bib-0012","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s00198-013-2460-0","article-title":"Mild morphometric vertebral fractures predict vertebral fractures but not nonvertebral fractures","volume":"25","author":"Johansson","year":"2014","journal-title":"Osteoporos Int"},{"issue":"1","key":"2024021014201056700_jbmr3163-bib-0013","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s00198-009-1034-7","article-title":"The potential impact of new National Osteoporosis Foundation guidance on treatment patterns","volume":"21","author":"Dawson-Hughes","year":"2010","journal-title":"Osteoporos Int"},{"key":"2024021014201056700_jbmr3163-bib-0014","year":"2008"},{"issue":"6","key":"2024021014201056700_jbmr3163-bib-0015","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1007\/s001980170087","article-title":"Standardization of bone mineral density at femoral neck, trochanter and Ward's triangle","volume":"12","author":"Lu","year":"2001","journal-title":"Osteoporos Int"},{"issue":"5","key":"2024021014201056700_jbmr3163-bib-0016","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1007\/s001980050093","article-title":"Updated data on proximal femur bone mineral levels of US adults","volume":"8","author":"Looker","year":"1998","journal-title":"Osteoporos Int"},{"issue":"7","key":"2024021014201056700_jbmr3163-bib-0017","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1359\/jbmr.2002.17.7.1237","article-title":"International variations in hip fracture probabilities: implications for risk assessment","volume":"17","author":"Kanis","year":"2002","journal-title":"J Bone Miner Res"},{"key":"2024021014201056700_jbmr3163-bib-0018","author":"Breslow"},{"key":"2024021014201056700_jbmr3163-bib-0019"},{"issue":"1","key":"2024021014201056700_jbmr3163-bib-0020","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1359\/jbmr.061008","article-title":"Clodronate reduces the incidence of fractures in community-dwelling elderly women unselected for osteoporosis: results of a double-blind, placebo-controlled randomized study","volume":"22","author":"McCloskey","year":"2007","journal-title":"J Bone Miner Res"},{"issue":"1","key":"2024021014201056700_jbmr3163-bib-0021","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s00198-011-1691-1","article-title":"Sustained efficacy and safety of bazedoxifene in preventing fractures in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled study","volume":"23","author":"Silverman","year":"2012","journal-title":"Osteoporos Int"},{"issue":"7","key":"2024021014201056700_jbmr3163-bib-0022","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1002\/jbmr.1606","article-title":"Denosumab reduces the risk of osteoporotic fractures in postmenopausal women, particularly in those with moderate to high fracture risk as assessed with FRAX","volume":"27","author":"McCloskey","year":"2012","journal-title":"J Bone Miner Res"},{"issue":"8","key":"2024021014201056700_jbmr3163-bib-0023","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1002\/jbmr.1625","article-title":"Effect of alendronate for reducing fracture by FRAX score and femoral neck bone mineral density: the Fracture Intervention Trial","volume":"27","author":"Donaldson","year":"2012","journal-title":"J Bone Miner Res"},{"issue":"33","key":"2024021014201056700_jbmr3163-bib-0024","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta5330","article-title":"Subgroup analyses in randomised controlled trials: quantifying the risks of false-positives and false-negatives","volume":"5","author":"Brookes","year":"2001","journal-title":"Health Technol Assess"}],"container-title":["Journal of Bone and Mineral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjbmr.3163","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/32\/8\/1625\/56652145\/jbmr3163.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/32\/8\/1625\/56652145\/jbmr3163.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T14:59:03Z","timestamp":1710341943000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmr\/article\/32\/8\/1625-1631\/7605547"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,5]]},"references-count":24,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2017,5,5]]},"published-print":{"date-parts":[[2017,8,1]]}},"URL":"https:\/\/doi.org\/10.1002\/jbmr.3163","relation":{},"ISSN":["0884-0431","1523-4681"],"issn-type":[{"value":"0884-0431","type":"print"},{"value":"1523-4681","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2017,8,1]]},"published":{"date-parts":[[2017,5,5]]}}}